Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entinostat + sorafenib
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Entinostat + sorafenib is a combination therapy consisting of entinostat, a selective histone deacetylase (HDAC) inhibitor, and sorafenib, a multikinase inhibitor. This combination was developed based on preclinical data demonstrating cytotoxic synergy between the two agents. Entinostat selectively inhibits class I HDACs (particularly HDAC1, HDAC2, and HDAC3), which are involved in gene expression regulation, while sorafenib targets multiple kinases involved in tumor growth and angiogenesis, including VEGFR, PDGFR, and RAF kinases.
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))PDGFRB (Platelet-derived growth factor receptor beta)VEGFR3 (Vascular endothelial growth factor receptor 3)HDAC (HDAC family)VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on entinostat + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entinostat + sorafenib.